Neurologist · Hospital Universitario 12 de Octubre and Director of the Memory Unit at Hospital Ruber Internacional
Dr. Víctor Antonio Blanco Palmero is a neurologist specialized in cognitive impairment, Alzheimer’s disease and other neurodegenerative disorders. He currently works in the Cognitive Impairment Unit at Hospital Universitario 12 de Octubre in Madrid and, since 2022, has served as Director of the Memory Unit at Hospital Ruber Internacional. His clinical activity is particularly focused on the diagnosis, treatment and longitudinal follow-up of patients with Alzheimer’s disease and other forms of dementia.
He graduated in Medicine from the University of Valladolid and completed his residency in Neurology at Hospital Universitario 12 de Octubre. During his specialist training, he undertook an international rotation at the Movement Disorders Unit of Columbia University Medical Center in New York. He subsequently joined the Cognitive Impairment Unit at Hospital 12 de Octubre, where he has participated in more than 20 clinical trials and is responsible for a dedicated Alzheimer’s disease clinic.
His academic and research career has focused on neurodegenerative diseases and biomarkers. He was awarded a two-year Río Hortega research fellowship within the Neurodegenerative Diseases Group at the i+12 Research Institute, where his work focused on biomarkers in neurodegenerative disorders. He has also collaborated in several competitively funded research projects, including studies on SORL1, Alzheimer’s disease and Lewy body disorders. He holds a Master’s degree in Research Design and Analysis in Health Sciences from Universitat Autònoma de Barcelona and completed advanced postgraduate training in Alzheimer’s disease at Universidad Francisco de Vitoria.
Dr. Blanco Palmero has authored or co-authored multiple scientific publications in the field of neurodegeneration, including work on Alzheimer’s disease biomarkers, cerebral amyloid angiopathy, SORL1-associated disease and amyloid-related imaging abnormalities (ARIA). His combined experience in clinical dementia care, clinical trials and biomarker-based research provides a strong translational perspective on the implementation and monitoring of emerging disease-modifying therapies for Alzheimer’s disease.
